1. SELECTED PUBLICATIONS
1. Wang L, Pollock N, Wallweber J, Gooding WE, Huang WD, Winslow J,. Grandis JR.
Increased expression of HER2 and HER3 in HPV-positive HNSCC using a novel proximity-
based assay. Clin Cancer Res. (Submitted)
2. Wang L, Chiosea S, Grandis JR. Differential pathological significance of subcellular
MDM2 expression in head and neck squamous cell carcinoma (HNSCC). (Manuscript)
3. Srivastava RM, Trivedi S, Concha-Benavente F, Jie HB, Wang L, Seethala RR, Branstetter
BF, Ferrone S, Ferris RL. STAT1 Induced HLA class I Upregulation Enhances Immunogenicity
and Clinical Response to anti-EGFR mAb Cetuximab Therapy in HNC Patients. Cancer
Immunol Res. 2015 May 13. pii: canimm.0053.2015. [Epub ahead of print]
4. Wheeler SE, Egloff AM, Wang L, James CD, Hammerman PS, Grandis JR. Challenges in
EGFRvIII detection in head and neck squamous cell carcinoma. PLoS One. 2015 Feb
6;10(2):e0117781.
5. Nakajima EC, Laymon C, Oborski M, Hou W, Wang L, Grandis JR, Ferris RL, Mountz JM,
Van Houten B. Quantifying Metabolic Heterogeneity in Head and Neck Tumors in Real Time:
2-DG Uptake Is Highest in Hypoxic Tumor Regions. PLoS One. 2014 Aug 15;9(8):e102452.
doi: 10.1371/journal.pone.0102452. eCollection 2014.
6. Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin
DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA. Phase II
study of cetuximab in combination with cisplatin and radiation in unresectable, locally
advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial
E3303. Clin Cancer Res. 2014 Oct 1;20(19):5041-51
7. Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea S, Hood BL,
Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, Wirth L, Nikiforova
MN, Siegfried JM, Grandis JR. Erlotinib, erlotinib-sulindac versus placebo: a randomized,
double-blind, placebo-controlled window trial in operable head and neck cancer. Clin Cancer
Res. 2014 Jun 15;20(12):3289-98.
8. Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ,
Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, Kim SH, Minata
M, Nakano I, Grandis JR, McLendon RE, Bigner DD, Lin HK, Furnari FB, Cavenee WK, Hu

2. B, Yan H, Cheng SY. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates
AKT-promoted tumorigenesis. J Clin Invest. 2014 Sep 2; 124 (9):3741-5.
9. Vaezi AE, Bepler G, Bhagwat NR, Malysa A, Rubatt JM, Chen W, Hood BL, Conrads TP,
Wang L, Kemp CE, Niedernhofer LJ. Choline phosphate cytidylyltransferase-α is a novel
antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung
and head and neck squamous cell carcinomas. Cancer. 2014 June 15; 120 (12): 1898-1907.
10. Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ,
Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, Du Y, Vries JK, Hammerman PS, Garraway LA,
Mills GB, Johnson DE, Grandis JR. Frequent mutation of receptor protein tyrosine
phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer; Proc
Natl Acad Sci U S A. 2014 Jan 21;111(3):1114-9.
11. Sen M, Paul K, Freilino ML, Li H, Li C, Johnson DE, Wang L, Eiseman J, Grandis JR.
Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3)
decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. Mol Med.
2014 Mar 18;20:46-56
12. Troy JD, Weissfeld JL, Youk AO, Thomas S, Wang L, Grandis JR. Expression of EGFR,
VEGF, and NOTCH1 Suggest Differences in Tumor Angiogenesis in HPV-Positive and HPV-
Negative Head and Neck Squamous Cell Carcinoma. Head Neck Pathol. Head Neck Pathol.
2013 Dec;7(4):344-55
13. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y,
Gilbert B, Freilino M, Sauerwein S, Peyser N, Xiao D, Diergaarde B, Wang L, Chiosea S,
Seethala RR, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Ng PK,
Garraway LA, Hammerman P, Mills GB, Grandis JR. Frequent mutation of the PI3K pathway
in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013 Jul;3(7):761-9.
14. Leibowitz MS, Srivastava RM, Andrade Filho PA, Egloff AM, Wang L, Seethala RR,
Ferrone S, Ferris RL. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component
expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer
cells. Clin Cancer Res. 2013 Feb 15;19(4):798-808.
15. Cassell A, Freilino ML, Lee J, Barr S, Wang L, Panahandeh MC, Thomas SM, Grandis JR.
Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer
preclinical models. Neoplasia. 2012 Nov;14(11):1005-14

3. 16. Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE,
Johnson DE, Grandis JR. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin
Cancer Res. 2012 Sep 15;18(18):4986-96. doi: 10.1158/1078-0432.CCR-12-0792.
17. Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N,
Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, Etter JP, Li PK, Wang L, Chiosea S,
Seethala RR, Gooding WE, Chen X, Kaminski N, Pandit K, Johnson DE, Grandis JR. First-in-
human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer
therapy. Cancer Discov. 2012 Aug;2(8):694-705. doi: 10.1158/2159-8290.
18. Wheeler SE, Siwak DR, Chai RL, Lavalle CR, Seethala RR, Wang L, Cieply KM, Sherer
C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM.Tumor epidermal growth
factor receptor (EGFR) and EGFR PY1068 are independent prognostic indicators for head and
neck squamous cell carcinoma. Clin Cancer Res. 2012 Apr 15;18(8):2278-89
19. Mburu YK, Egloff AM, Walker WH, Wang L, Seethala RR, van Waes C, Ferris RL.
Chemokine receptor 7 (CCR7) gene expression is regulated by NF-κB and activator protein 1
(AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN). J Biol Chem. 2012
Jan 27;287(5):3581-90.
20. Argiris A, Lee SC, Feinstein T, Thomas S, Branstetter BF 4th, Seethala R, Wang L,
Gooding W, Grandis JR, Ferris RL. Serum biomarkers as potential predictors of antitumor
activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral
Oncol. 2011 Oct;47(10):961-6
21. Argiris A, Feinstein TM, Wang L, Yang T, Agrawal S, Appleman LJ, Stoller RG, Grandis
JR, Egloff AM. Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with
advanced solid malignancies. Invest New Drugs. 2011 Sep 1
22. Vaezi A, Wang X, Buch S, Gooding W, Wang L, Seethala RR, Weaver DT, D'Andrea AD,
Argiris A, Romkes M, Niedernhofer LJ, Grandis JR. XPF expression correlates with clinical
outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2011 Aug
15;17(16):5513-22.
23. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV,
Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D,
Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M,
Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-
Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES,

4. Getz G, Golub TR, Garraway LA, Grandis JR. The Mutational Landscape of Head and Neck
Squamous Cell Carcinoma. Science 26 August 2011: Vol. 333 no. 6046 pp. 1157-1160.
24. Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, Branstetter BF, Posluszny
DM, Wang L, Seethala RR, Dacic S, Gooding W, Grandis JR, Johnson JT, Ferris RL.
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin,
and cetuximab and maintenance cetuximab in patients with locally advanced head and neck
cancer. J Clin Oncol. 2010 Dec 20; 28(36):5294-300.
25. Kropf PL, L Wang, Y Zang, RL Redner and DE Johnson. Dasatinib promotes ATRA-
induced differentation of AML cells. Leukemia 24(3):663-665, 2010.
26. JE Jones, L Wang, PL Kropf, R Duan, DE Johnson. Src family kinase gene targets during
myeloid differentiation: identification of the EGR-1 gene as a direct target. Leukemia. 2009
October; 23(10): 1933–1935.
27. Kim SI, Kwak JH, Wang L, Choi ME. Protein phosphatase 2A is a negative regulator of
transforming growth factor-beta 1-induced TAK1 in mesangial cells. J Biol Chem. 2008 Apr
18; 283(16):10753-10763.
28. Wang L, Lee JY, Kwak JH, He Y, Kim SI, Choi ME.Protective effects of low-dose carbon
monoxide against renal fibrosis induced by unilateral ureteral obstruction. Am J Physiol Renal
Physol. 2008 Mar; 294(3):F508-517.
29. Kim SI, Kwak JH, Zachariah M, He Y, Wang L, Choi ME TGF-beta - activated kinase 1
and TAK1-binding protein 1 cooperate to mediate TGF-beta1-induced MKK3-p38 MAPK
activation and stimulation of type I collagen. Am J Physiol Renal Physiol. 2007 May;
292(5):F1471- 1478.
30. Wang L, Kwak JH, Kim SI, He Y, Choi ME. Transforming growth factor-beta1 stimulates
vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3-p38alpha
and p38delta mitogen-activated protein kinase-dependent pathway in murine mesangial cells. J
Biol Chem. 2004 Aug 6; 279 (32):33213-33219.
31. Wang L, Ma R, Flavell RA, Choi ME.Requirement of Mitogen-activated Protein Kinase
Kinase 3 (MKK3) for Activation of p38 α and p38 δ MAPK isoforms by TGF-ß1 in murine
mesangial cells. J Biol Chem 2002 Dec 6; 277 (49), 47257-47262.

5. 32. Wang L, Xiong M, Che DY, et al. Effect of hypoxia on proliferation and differentiation of
the pulmonary vascular pericytes. Chinese Journary of Tuberculosis and Respiratory Disease,
1999, 22(3):176-178.
PRESENTATIONS
1. Mitogen-Activated Protein Kinase Kinase 3 (MKK3) Mediates Activation of p38 MAPK by
TGF-beta1 in Mesangial Cells. (Poster), ASN (America Society of Nephrology) conference,
San Francisco, California, Oct, 2001
2. Selective Activation of p38 MAPK Isoforms p38 alpha and p38delta by TGF-beta1 Is
Mediated Via Mitogen-Activated Protein Kinase Kinase (MKK3) in Mouse Mesangial Cells.
(Oral), ASN (America Society of Nephrology) conference, Philadelphia, Pennsylvania, Nov,
2002
3. Mitogen-Activated Protein Kinase Kinase 3 (MKK3)-p38MAPK (p38 alpha and p38 delta)
Pathway Mediates TGF- beta1 induced – Expression of Vascular Endothelial Growth Factor
(VEGF) in Mouse Mesangial Cells. (Poster), ASN (America Society of Nephrology)
conference, San Diego, Nov, 2003
4. Protective Effects of Carbon Monoxide (CO) To Inhibit Renal Fibrosis in Obstructive
Nephropathy. (Poster), ASN (America Society of Nephrology) conference, St. Louis, Missouri,
Nov, 2004
5. Protective effects of low-dose carbon monoxide (CO) against renal fibrosis induced by
unilateral ureteral obstruction. (Oral), Research Day, Department of Medicine, University of
Pittsburgh School of Medicine, May, 2006
6. Carbon monoxide (CO) inhibits profibrotic effects of TGF-ß1 in renal tubular epithelial
cells, via the MKK3-p38β MAPK pathway. (Poster), American Society of Nephrology (ASN)
conference. Philadelphia, Pennsylvania, Nov , 2006